



Hyper-accelerate Drug Development

The screenshot displays the InSilicoTrials web application interface. The top navigation bar includes the company logo, "Products", "Resources", "Company", "Platform Login", and "Get Started". The main content area features a "QT/TdP Risk Screen" section with a description: "A unique tool able to calculate safety markers and estimate in minutes clinical risks following CredibleMeds classification for multiple concentrations of a compound against the four most relevant ion currents." Below this is a "Log in" button. To the right, there is a table titled "ACTIVITY" with a "Run test" button. The table lists products and their outcomes:


Compounds	Conc. (nM)	Outcome
Product A	412.9	SAFE
Product B	81	UNSAFE
Product C	4.9	PROB UNSAFE
Product D	120.6	SAFE
Product E	426.2	SAFE
Product F	412.9	PROB UNSAFE
Product G	412.9	UNSAFE

Below the table, there is a "NuMRis" section. On the far right, a "QT/TdP Risk Screen" summary card shows "124 Compounds". Below that, another "ACTIVITY" card displays a large gauge with the number "432" and "Conc. (nM)". The footer contains logos for "Who talks about us", "MIT Technology Review", "WORLD PHARMA TODAY", "STARTUP + HEALTH", "FORTUNE", "StartupItalia", and "Forbes".

Our MISSION is to revolutionize
drug development with the power
of *in silico* technology

Today's Problem

Development of new products in Pharma is challenging




\$2.6BN

Average investment to develop a new drug



12 Years

Average time to get drugs over the finish line



5%

Average percentage of novel drugs approved by regulators




ROI

1.2 %, 2022 ROI on Pharma R&D spending, lowest in last 13 years

FDA and EU Parliament are endorsing strong innovation in clinical trials.

Solution

Cutting-edge AI and Modeling & Simulation platform to predict clinical trial outcomes



InSilicoTrials Platform features models from world-renowned scientific institutions and regulatory bodies such as the FDA, fully aligned with guidelines from both the FDA and EMA.


Engagement in Regulatory Science

We are co-editor of the book *Toward Good Simulation Practice*




Boston Scientific Medtronic
Johnson & Johnson

&



FDA U.S. FOOD & DRUG
ADMINISTRATION




“The implementation of Good Simulation Practice is seen as a key factor in ensuring the sustained success of M&S in the healthcare field.”

Pras Pathmanathan
Office of Science and Engineering Laboratories |
Center for Devices and Radiological Health | U.S.
Food and Drug Administration

Value Proposition

Nonclinical and Clinical Trials Simulations



Benefits

AI-generated **prognostic digital twins** for clinical trials simulation in **MS**



Multiple sclerosis disease progression and treatment effect prediction on more than 3.000 MS Virtual Patients in just 1 day of simulation time

Estimated Savings:

€20Mil

4 years of clinical trial time

Benefits

Multiple clinical trials simulations in CNS



Testing the compound in diverse disease progression models in CNS

Client-Identified Advantages

- ✓ De-risk clinical plan with safety simulations
- ✓ Discover new indications and unlock market potential without clinical trial execution costs

Estimated Savings:

€30 Mil

3 years of clinical trial time

Main Collaborations



Strong Experience in Digital Simulation Pharma and MedTech



Luca Emili
CEO & Founder
M.S. in Economics

Serial Entrepreneur,
20+ years track record
in IT and Cybersecurity



Mario Torchia
Chief Operating Officer
M.Eng. in Computer Science

+14 years in healthcare
and M&S. Former Executive
of Dassault Systèmes



Matteo Gazzin
Engineering Manager
M.Eng. in Computer Science

+10 years in numerical
Optimization and simulation
data management



Mark Lovern
Chief Plattform Officer
PhD. Biomathematics

25+ years of experience in the
application of model-informed drug
development (MIDD)

Advisors



Stefano Bini | Academia
CTO University
of California
San Francisco



Guido Rasi | Regulator
Former Executive
Director at EMA
Rome



Alessandro De Luca | BigPharma
CIO Merck
Darmstadt



Michael Eckstut | M&S Platform
Former Senior Vice
President
New Jersey



The Team

7 Nationalities

29 employees

(majority with Ph.D. or
MBA)

**We are ready for the future of
medicine, are you?**

Thank you.